NCT04859946View on ClinicalTrials.gov

Itacitinib for the Prevention of Graft Versus Host Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Hematologic and Lymphocytic Disorder
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo stem cell transplant

DRUG

Busulfan

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

DRUG

Itacitinib

Given PO

DRUG

Tacrolimus

Given IV or PO

DRUG

Thiotepa

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT04859946 - Itacitinib for the Prevention of Graft Versus Host Disease | Biotech Hunter | Biotech Hunter